Evaluation of central serotonergic function in affective and related disorders by the fenfluramine challenge test: A critical review

International Journal of Neuropsychopharmacology

Volumn 1, Issue 1, 1998, Pages 49-69

  Newman, Michael E ^a   Shapira, Baruch ^b   Lerer, Bernard ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b HERZOG HOSPITAL   (Israel)

Author keywords

Cortisol; Depression; Fenfluramine; Prolactin; Serotonin

Indexed keywords

EID: 0003001681     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145798001072     Document Type: Review

References (144)

1. Abel KM, O'Keane V, Murray RM, Cleare AJ (1997). Serotonergic function and negative and depressive symptomatology in schizophrenia and major depression. Psychoneuroendocrinology 22, 539-548.
2. Abenhaim L, Moride Y, Brenot F et al. (1996). Appetite-suppressant drugs and the risk of primary pulmonary hypertension. New England Journal of Medicine 335, 609-616.
3. Albinsson A, Palazidou E, Stephenson J, Andersson G (1994). Involvement of the 5-HT-2 receptor in the 5-HT receptor-mediated stimulation of prolactin release. European Journal of Pharmacology 251, 157-161.
4. American Psychiatric Association (1989). Diagnostic and Statistical Manual of Mental Disorders (3rd edition revised) Washington DC: American Psychiatric Association.
5. Apostolopoulos M, Judd FK, Burrows GD, Norman TR (1993). Prolactin responses to dl-fenfluramine in panic disorder. Psychoneuroendocrinology 18, 337-342.
6. Asnis GM, Eisenberg J, van Praag HM, Lemus CZ, Friedman H, Miller AH (1988). The neuroendocrine response to fenfluramine in depressives and normal controls. Biological Psychiatry 24, 117-120.
7. Aulakh CS, Zohar J, Wozniak KM, Hill JL, Haass M, Murphy DL (1991). Differential effects of antidepressant treatments on fenfluramine-induced increases in plasma prolactin and corticosterone in rats. Pharmacology, Biochemistry and Behavior 39, 91-95.
8. Bancroft J, Cook A (1995). The neuroendocrine response to d-fenfluramine in women with premenstrual depression. Journal of Affective Disorders 36, 57-64.
9. Barbieri C, Sala M, Bigatti C, Rauhe WG, Guffanti A, Diena A, Scorza D, Bevilacqua M, Norbiato G (1984). Serotonergic regulation of cortisol secretion in dogs. Endocrinology 115, 748-751.
10. Baumgartner A, Graf K-J, Kurten I (1988). Prolactin in patients with major depressive disorder and in healthy subjects: cross-sectional study of basal and post-TRH and post-dexamethasone prolactin levels. Biological Psychiatry 24, 249-267.
11. Bearn J, Allain T, Coskeran P, Munro N, Butler J, McGregor A, Wessely S (1995). Neuroendocrine responses to d-fenfluramine and insulin-induced hypoglycemia in chronic fatigue syndrome. Biological Psychiatry 37, 245-252.
12. Bonanno G, Fassio A, Severi P, Ruelle A, Raiteri M (1994). Fenfluramine releases serotonin from human brain nerve endings by a dual mechanism. Journal of Neurochemistry 63, 1163-1166.
13. Bond AJ, Feizollah S, Lader MH (1995). The effects of d-fenfluramine on mood and performance, and on neuroendocrine indicators of 5-HT function. Journal of Psychopharmacology 9, 1-8.
14. Carboni E, di Chiara G (1989). Serotonin release estimated by transcortical dialysis in freely-moving rats. Neuroscience 32, 637-645.
15. Cleare AJ, Bearn J, Allain T, McGregor A, Wessely S, Murray RM, O'Keane V (1995). Contrasting neuroendocrine responses in depression and chronic fatigue syndrome. Journal of Affective Disorders 35, 283-289.
16. Cleare AJ, Bond AJ (1997). Does central serotonergic function correlate inversely with aggression? A study using d-fenfluramine in healthy subjects. Psychiatry Research 69, 89-95.
17. Cleare AJ, Murray RM, O'Keane V (1996). Reduced prolactin and cortisol responses to d-fenfluramine in depressed compared to healthy matched control subjects. Neuropsychopharmacology 14, 349-354.
18. Cleare AJ, Murray RM, O'Keane V (1997). Do noradrenergic reuptake inhibitors affect serotonergic function in depression? Psychopharmacology 134, 406-410.
19. Coccaro EF, Herman ME, Kavoussi RJ, Hauger RL (1996d). Relationship of prolactin response to d-fenfluramine to behavioural and questionnaire assessments of aggression in personality-disordered men. Biological Psychiatry 40, 157-164.
20. Coccaro EF, Kavoussi RJ (1994). Neuropsychopharmacologic challenge in biological psychiatry. Clinical Chemistry 40, 319-327.
21. Coccaro EF, Kavoussi RJ, Oakes M, Cooper TB, Hauger R (1996a). 5-HT-2a/2c receptor blockade by amesergide fully attenuates prolactin response to d-fenfluramine challenge in physically healthy human subjects. Psychopharmacology 126, 24-30.
22. Coccaro EF, Kavoussi RJ, Cooper TB, Hauger R (1996b). 5-HT3 antagonism by ondansetron does not attenuate prolactin response to d-fenfluramine challenge in healthy human subjects. Psychopharmacology 127, 105-112.
23. Coccaro EF, Kavoussi RJ, Cooper TB, Hauger R (1996c). Hormonal responses to d- and l-fenfluramine in healthy human subjects. Neuropsychopharmacology 15, 595-607.
24. Coccaro EF, Kavoussi RJ, Cooper TB, Hauger RL (1997a). Central serotonin activity and aggression: inverse relationship with prolactin response to d-fenfluramine, but not CSF 5-HIAA concentrations, in human subjects. American Journal of Psychiatry 154, 1430-1435.
25. Coccaro EF, Kavoussi RJ, Trestman RL, Gabriel SM, Cooper TB, Siever LJ (1997b). Serotonin function in human subjects: intercorrelations among central 5-HT indices and aggressiveness. Psychiatry Research 73, 1-14.
26. Coccaro E, Klar H, Siever LJ (1994b). Reduced prolactin response to fenfluramine challenge in personality disorder patients is not due to deficiency of pituitary lactotrophs. Biological Psychiatry 36, 344-34.
27. Coccaro EF, Siever LJ, Klar H, Rubenstein K, Benjamin E, Davis KL (1987). Diminished prolactin responses to repeated fenfluramine challenge in man. Psychiatry Research 22, 257-259.
28. Coccaro EF, Siever LJ, Klar HM, Cochrane K, Cooper TB, Mohs RC, Davis KL (1989). Serotonergic studies in patients with affective and personality disorders: correlates with suicidal and impulsive-aggressive behaviour. Archives of General Psychiatry 46, 587-599.
29. Coccaro EF, Silverman JM, Klar HM, Horvath TB, Siever LJ (1994a). Familial correlates of reduced central serotonergic system function in patients with personality disorders. Archives of General Psychiatry 51, 318-324.
30. Coiro V, Volpi R, Marchesi C, deFerri A, Davioli C, Caffara P, Rossi G, Caffari G, Davolio M, Chiodera P (1993). Abnormal serotonergic control of prolactin and cortisol secretion in patients with seasonal affective disorder. Psychoneuroendocrinology 18, 51-556.
31. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV (1997). Valvular heart disease associated with fenfluramine-phentermine. New England Journal of Medicine 337, 581-588.
32. Curzon G, Gibson EL, Oluyomi AO (1997). Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability. Trends in Pharmacological Science 18, 21-25.
33. Dinan TG (1996). Serotonin and the regulation of hypothalamic-pituirary-adrenal axis function. Life Sciences 58, 1683-1694.
34. Dinan TG, O'Keane V (1992). Reply to letter 'Elevated cortisol concentrations and the diminished prolactin response to fenfluramine' by Mitchell PB, Smythe GA. American Journal of Psychiatry 149, 851-852.
35. Dinan TG, Scott LV (1996). The influence of cortisol on spontaneous and 5-HT stimulated prolactin release in man. Journal of Basic Clinical Physiology and Pharmacology 7, 45-56.
36. DiRenzo G, Amoroso S, Taglialatela M, Canzoniero L, Basile V, Fatatis A, Annunziato L (1989). Pharmacological characterization of serotonin receptors involved in the control of prolactin secretion. European Journal of Pharmacology 162, 371-373.
37. Fineberg NA, Roberts A, Montgomery SA, Cowen PJ (1997). Brain 5-HT function in obsessive-compulsive disorder: prolactin responses to d-fenfluramine. British Journal of Psychiatry 171, 280-282.
38. Fishbein DH, Lozovsky D, Jaffe JH (1989). Impulsivity, aggression and neuroendocrine responses to serotonergic stimulation in substance abusers. Biological Psychiatry 25, 1049-1066.
39. FitzGerald M, Malone K, Li S, Harrison WM, McBride PA, Endicott J, Cooper T, Mann JJ (1997a). Blunted serotonin response to fenfluramine challenge in premenstrual dysphoric disorder. American Journal of Psychiatry 54, 556-558.
40. FitzGerald M, Malone K, Li S, Suckow R, Mann JJ (1997b). Plasma tryptophan levels and prolactin response to fenfluramine in healthy volunteers. Biological. Psychiatry 42, 416-418.
41. Garattini S, Caccia S, Mennini T, Samanin R, Cinsolo S, Ladinsky H (1979). Biochemical pharmacology of the anorectic drug fenfluramine: a review. Current Medical Research and Opinion (Supplement) 6, 15-27.
42. Gerra G, Fertonani G, Tagliavini P, Zaimovic A, Delsignore R, Maestri D, Avanzini P, Caccavari R, Brambilla F (1995). Serotonin function in detoxified heroin abusers: prolactin and cortisol responses to fenfluramine challenge. Psychiatry Research 58, 153-160.
43. Gerra G, Caccavari R, Zaimovic A , Palladino M, Chittolini B, Giucastro G, Maestri D, Monica C, Fertonani-Affini G, Delsignore R, Brambilla F (1997). Serotonergic function in mothers of opiate addicts: correlation with comorbid depression. Acta Psychiatrica Scandinavica 96, 36-42.
44. Gibson EL, Kennedy AJ, Curzon G (1993). D-fenfluramine and d-norfenfluramine-induced hypophagia: differential mechanisms and involvement of postsynaptic 5-HT receptors. European Journal of Pharmacology 242, 83-90.
45. 3H]-5-hydroxytryptamine induced by d-fenfluramine in rat hippocampal synaptosomes. European Journal of Pharmacology 238, 9-17.
46. Goodall IM, Cowen PJ, Franklin M, Silverstone T (1993). Ritanserin attenuates anorectic, endocrine and thermic responses to d-fenfluramine in human volunteers. Psychopharmacology 112, 461-466.
47. Goodwin GM, Murray CL, Bancroft J (1994). Oral d-fenfluramine and neuroendocrine challenge: problems with the 30 mg dose in men. Journal of Affective Disorders 30, 117-122.
48. Gorard DA, Taylor TM, Medbak SH, Perry LA, Libby GW, Farthing MJG (1993). Plasma prolactin, adrenocorticotrophic hormone and cortisol after administration of d-fenfluramine or placebo to healthy subjects. International Clinical Psychopharmacology 8, 123-128.
49. Halperin JM, Sharma V, Siever LJ, Schwartz ST, Malier K, Wornell G, Newcorn JH (1994). Serotonergic function in aggressive and nonaggressive boys with attention deficit hyperactivity disorder. American Journal of Psychiatry 151, 243-248.
50. Halperin JM, Newcorn JH, Schwartz ST, Sharma V, Siever LJ, Koda VH, Gabriel S (1997). Age-related changes in the association between serotonergic function and aggression in boys with ADHD. Biological Psychiatry 41, 682-689.
51. Hewlett WA, Vinogradov S, Martin K, Berman S, Csernansky JG (1992). Fenfluramine stimulation of prolactin in obsessive-compulsive disorder. Psychiatry Research 42, 81-92.
52. Hollander E, deCaria CM, Nitescu A, Gully R, Suckow RF, Cooper TB, Gorman JM, Klein DF, Liebowitz MR (1992). Serotonergic function in obsessive-compulsive disorder. Archives of General Psychiatry 49, 21-28.
53. Hollander E, Cohen LJ, deCaria CM, Saoud JB, Stein DJ, Cooper TB, Islam NN, Liebowitz MR, Klein DF (1993). Timing of neuroendocrine responses and effect of m-CPP and fenfluramine plasma levels in OCD. Biological Psychiatry 34, 407-413.
54. Invernizzi R, Berettera C, Garattini S, Samanin R (1986). D-and l-isomers of fenfluramine differ markedly in their interaction with brain serotonin and catecholamines in the rat. European Journal of Pharmacology 120, 9-15.
55. Judd FK, Apostolopoulos M, Burrows GD, Norman TR (1994). Serotonergic function in panic disorder: endocrine responses to d-fenfluramine. Progress in Neuropsychopharmacology and Biological Psychiatry 18, 329-337.
56. Kasper S, Vieira A, Schmidt R, Richter P (1990). Multiple hormone responses to stimulation with dl-fenfluramine in patients with major depression before and after antidepressive treatment. Pharmacopsychiatry 23, 76-84.
57. Kleven MS, Seiden LS (1989). D-, l- and dl-fenfluramine cause long-lasting depletions of serotonin in rat brain. Brain Research 505, 351-353.
58. Kreiss DS, Wieland S, Lucki I (1993). The presence of a serotonin uptake blocker alters pharmacological manipulations of serotonin release. Neuroscience 52, 295-301.
59. Kuhn CM, Vogel RA, Mailman RB, Mueller RA, Schanberg SM, Breese GR (1981). Effect of 5,7-dihydroxytryptamine on serotonergic control of prolactin secretion and behaviour in rats. Psychopharmacology 73, 188-193.
60. Laferrere B, Wurtman RJ (1989). Effects of d-fenfluramine on serotonin release in brain of anesthetized rats. Brain Research 504, 258-263.
61. Lerer B, Ran A, Blacker M, Silver H, Weller MPI, Drummer D, Ebstein B, Calev A (1988). Neuroendocrine responses in chronic schizophrenia: evidence for serotonergic dysfunction. Schizophrenia Research 1, 405-410.
62. Lerer B, Gillon D, Lichtenberg P, Gorfine M, Gelfin Y, Shapira B (1996). Interrelationship of age, depression and central serotonergic function: evidence from fenfluramine challenge studies. International Psychogeriatrics 8, 83-102.
63. Levy AD, van de Kar LD (1992). Endocrine and receptor pharmacology of serotonergic anxiolytics, antipsychotics and antidepressants. Life Sciences 51, 83-94.
64. Levy AD, Li Q, van de Kar LD (1994). Repeated cocaine exposure inhibits the adrenocorticotrophic hormone response to the serotonin releaser d-fenfluramine and the 5-HT-1a agonist 8-OH-DPAT. Neuropharmacology 33, 335-342.
65. Lewis DA, Sherman BM (1984). Serotonergic stimulation of adrenocorticotropin secretion in man. Journal of Clinical Endocrinology and Metabolism 58, 458-462.
66. Li Q, Brownfield MS, Battaglia G, Cabrera TM, Levy AD, Rittenhouse PA, van de Kar LD (1993). Long-term treatment with the antidepressants fluoxetine and desipramine potentiates endocrine responses to the serotonin agonists MK-212 and DOI. Journal of Pharmacology and Experimental Therapeutics 266, 836-844.
67. Lichtenberg P, Shapira B, Gillon D, Kindler S, Cooper TB, Newman ME, Lerer B (1992). Hormone responses to fenfluramine and placebo challenge in endogenous depression. Psychiatry Research 43, 137-146.
68. Lopez-Ibor JJ, Saiz-Ruiz JJ, Iglesias LM (1989). Neuroendocrine challenges in the diagnosis of depressive disorders. British Journal of Psychiatry 154 (Supplement 4), 73-76.
69. Lopez-Ibor JJ, Lana F, Saiz-Ruiz JJ (1990). Impulsive suicidal behaviour and serotonin. Actas Luso Espanolas di Neurologia Psiquiatria y Ciencias Afines 18, 316-325.
70. Lucey JV, O'Keane V, Butcher G, Clare AW, Dinan TG (1992). Cortisol and prolactin responses to d-fenfluramine in non-depressed patients with obsessive-compulsive disorder: a comparison with depressed and healthy controls. British Journal of Psychiatry 161, 517-521.
71. Lucey JV, Butcher G, Clare AW, Dinan TG (1993). The anterior pituitary responds normally to protirelin in obsessive-compulsive disorder: evidence to support a neuroendocrine serotonergic deficit. Acta Psychiatrica Scandinavica 87, 384-388.
72. Maes M, Jacobs MP, Suy E, Minner B, Raus J (1989). Cortisol, ACTH, prolactin and beta-endorphin responses to fenfluramine in major depressed patients. Neuropsychobiology 21, 192-196.
73. Maes M, D'hondt P, Suy E, Vandervorst C, Raus J (1991). HPA-axis hormones and prolactin responses to dextrofenfluramine in depressed patients and healthy controls. Progress in Neuropsychopharmacology and Biological Psychiatry 15, 781-790.
74. Malone KM, Corbitt EM, Li S, Mann JJ (1996). Prolactin response to fenfluramine and suicide attempt lethality in major depression. British Journal of Psychiatry 168, 324-329.
75. Mann JJ, Malone KM, Diehl DJ, Perel J, Cooper TB, Mintun MA (1996). Demonstration in vivo of reduced serotonergic responsitivity in the brain of untreated depressed patients. American Journal of Psychiatry 153, 174-182.
76. Mann JJ, McBride PA, Brown RP, Linnoila M, Leon AC, DeMeo M, Mieczkowski T, Meyers JE, Stanley M (1992). The relationship between central and peripheral serotonin indices in depressed and suicidal psychiatric inpatients. Archives of General Psychiatry 49, 442-446.
77. Mann JJ, McBride PA, Malone KM, DeMeo M, Keilp J (1995). Blunted serotonergic responsivity in depressed inpatients. Neuropsychopharmacology 13, 53-64.
78. Mannel M, Muller-Oerlinghausen B, Czernik A, Sauer H (1997). 5-HT brain function in affective disorder: d,l-fenfluramine-induced hormone release and clinical outcome in long-term lithium/carbamazepine prophylaxis. Journal of Affective Disorders 46, 101-113.
79. Mark EJ, Patalas ED, Chang HT, Evans RJ, Kessler SC (1997). Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine. New England Journal of Medicine 337, 602-606.
80. McBride PA, DeMeo M, Sweeney JA, Halper J, Mann JJ, Shear MK (1992). Neuroendocrine and behavioural responses to challenge with the indirect serotonin agonist dl-fenfluramine in adults with obsessive-compulsive disorder. Biological Psychiatry 31, 19-34.
81. McBride PA, Tierney H, DeMeo M, Chen J-S, Mann JJ (1990). Effects of age and gender on CNS serotonergic responsitivity in normal adults. Biological Psychiatry 27, 1143-1155.
82. McCann UD, Yuan J, Ricaurte GA (1995). Fenfluramine's appetite suppression and serotonin neurotoxicity are separable. European Journal of Pharmacology 283, R5-R7.
83. McCann UD, Hatzidimitriou G, Ricaurte GA (1996). Prolactin response to fenfluramine is independent of serotonin release. European Journal of Pharmacology 312, R1-R2.
84. McCann UD, Seiden LS, Rubin LJ, Ricaurte GA (1997). Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine. Journal of the American Medical Association 278, 666-672.
85. McElroy JF, Miller JM, Meyer JS (1984). Fenfluramine, p-chloroamphetamine and p-fluoroamphetamine stimulation of pituitary-adrenocortical activity in rat: evidence for differences in site and mechanism of action. Journal of Pharmacology and Experimental Therapeutics 228, 593-599.
86. Mennini T, Garattini S, Caccia S (1985). Anorectic effect of fenfluramine isomers and metabolites: relationship between brain levels and in vitro potencies on serotonergic mechanisms. Psychopharmacology 85, 111-114.
87. Mitchell P, Smythe G, Parker G, Wilhelm K, Hickie I, Brodaty H, Boyce P (1990). Hormonal responses to fenfluramine in depressive subtypes. British Journal of Psychiatry 157, 551-557.
88. Mitchell P, Smythe G (1990). Hormonal responses to fenfluramine in depressed and control subjects. Journal of Affective Disorders 19, 43-51.
89. Mitchell PB, Smythe GA (1991). Endocrine and amine reponses to d,l-fenfluramine in normal subjects. Psychiatry Research 39, 141-153.
90. Monteleone P, Bortolotti F, Orazzo C, Serino I, Maj M (1997a). Differences between morning and afternoon hormonal responses to d-fenfluramine in healthy humans. Psychoneuroendocrinology 22, 79-87.
91. Monteleone P, Catapano F, Bortolotti F, Maj M (1997b). Plasma prolactin response to d-fenfluramine in obsessive-compulsive patients before and after fluvoxamine treatment. Biological Psychiatry 42, 175-180.
92. Monteleone P, Catapano F, Tortorella A, Maj M (1997c). Cortisol response to d-fenfluramine in patients with obsessive-compulsive disorder and in healthy subjects: evidence for a gender-related effect. Neuropsychobiology 36, 8-12.
93. Muhlbauer HD, Muller-Oerlinghausen B (1985). Fenfluramine stimulation of serum cortisol in patients with major affective disorders and healthy controls: further evidence for a central serotonergic action of lithium in man. Journal of Neural Transmission 61, 81-94.
94. Muhlbauer HD (1984). The influence of fenfluramine stimulation on prolactin plasma levels in lithium long-term treated manic-depressive patients and healthy subjects. Pharmacopsychiatry 17, 191-193.
95. Muldoon MF, Manuck SB, Jansma CL, Moore AL, Perel J, Mann JJ (1996). DL-fenfluramine challenge test; experience in non-patient sample. Biological Psychiatry 39, 761-768.
96. Neill JC, Cooper SJ (1989). Evidence that d-fenfluramine anorexia is mediated by 5-HT-1 receptors. Psychopharmacology 97, 213-218.
97. New AS, Trestman RL, Mitropoulou V, Benishay DS, Coccaro EF, Silverman J, Siever LJ (1997). Serotonergic function and self-injurious behaviour in personality disorder patients. Psychiatry Research 69, 17-26.
98. Oluyomi AO, Gibson EL, Barnfield AMC, Curzon G (1994). D-fenfluramine and d-norfenfluramine hypophagias do not require increased hypothalamic 5-hydroxytryptamine release. European Journal of Pharmacology 264, 111-115.
99. O'Keane V, Dinan TG (1991). Prolactin and cortisol responses to d-fenfluramine in major depression: evidence for diminished responsitivity of central serotonergic function. American Journal of Psychiatry 148, 1009-1015.
100. O'Keane CV, O'Hanlon M, Webb M, Dinan T (1991). D-fenfluramine/prolactin response throughout the menstrual cycle: evidence for an estrogen-induced alteration. Clinical Endocrinology 34, 289-292.
101. O'Keane V, McLoughlin D, Dinan TG (1992a). D-fenfluramine-induced prolactin and cortisol release in major depression: response to treatment. Journal of Affective Disorders 26, 143-150.
102. O'Keane V, Moloney E, O'Neill H, O'Connor A, Smith C, Dinan TG (1992b). Blunted prolactin responses to d-fenfluramine in sociopathy: evidence for subsensitivity of central serotonergic function. British Journal of Psychiatry 160, 643-646.
103. Oliver C, Jezova D, Grino M, Guillaume V, Boudouresque F, Conte-Devolx B, Pesce G, Dutour A, Becquet D (1990). Differences in the effects of acute and chronic administration of dexfenfluramine on cortisol and prolactin secretion. Advances in Experimental Medicine and Biology 274, 427-443.
104. Palazidou E, Stephenson J, Butler J, Coskeran P, Chambers S, McGregor AM (1995). Evidence for 5-hydroxytryptamine-1a receptor involvement in the control of prolactin secretion in man. Psychopharmacology 119, 311-314.
105. Park SBG, Cowen PJ (1995). Effect of pindolol on the prolactin response to d-fenfluramine. Psychopharmacology 118, 471-474.
106. Park SBG, Williamson DJ, Cowen PJ (1996). 5-HT neuroendocrine function in major depression: prolactin and cortisol responses to d-fenfluramine. Psychological Medicine 26, 1191-1196.
107. Pine DS, Coplan JD, Wasserman GA, Miller LS, Fried JE, Davies M, Cooper TB, Greenhill L, Shaffer D, Parsons B (1997). Neuroendocrine response to fenfluramine challenge in boys. Associations with aggressive behaviour and adverse rearing. Archives of General Psychiatry 54, 839-846.
108. Power AC, Cowen PJ (1992). Neuroendocrine challenge tests: assessment of 5-HT function in anxiety and depression. Molecular Aspects of Medicine 13, 205-220.
109. Power AC, Dorkins CE, Cowen PJ (1993). Effect of lithium on the prolactin response to d-fenfluramine in healthy subjects. Biological Psychiatry 33, 801-805.
110. Quattrone A, DiRenzo GF , Schettini G, Tedeschi G, Scopacasa F (1978). Increased plasma prolactin levels induced in rats by d-fenfluramine: relation to central serotonergic stimulation. European Journal of Pharmacology 49, 163-167.
111. Quattrone A, Schettini G, DiRenzo G, Tedeschi G, Preziosi P (1979). Effect of midbrain raphe lesion of 5,7-dihydroxytryptamine treatment on the prolactin-releasing action of quipazine and d-fenfluramine. Brain Research 174, 71-79.
112. Quattrone A, Tedeschi G, Aguglia U, Scopacasa F, DiRenzo GF, Annunziato L (1983). Prolactin secretion in man: a useful tool to evaluate the activity of drugs on central 5-hydroxytryptaminergic neurones. Studies with fenfluramine. British Journal of Clinical Pharmacology 15, 471-475.
113. Raiteri M, Bonanno G, Vallebuona F (1995). In vitro and in vivo effects of d-fenfluramine: no apparent relation between 5-hydroxytryptamine release and hypophagia. Journal of Pharmacology and Experimental Therapeutics 273, 643-649.
114. Sabol KE, Richards JB, Seiden LS (1992). Fluoxetine attenuates the dl-fenfluramine-induced increase in extracellular serotonin as measured by in vivo dialysis. Brain Research 585, 421-424.
115. Sarkissian CT, Wurtman RJ, Morse AN, Gleason R (1990). Effects of fluoxetine or d-fenfluramine on serotonin release from, and levels in, rat frontal cortex. Brain Research 529, 294-301.
116. Schurmeyer TH, Brademann G, von zur Muhlen A (1996). Effect of fenfluramine on episodic ACTH and cortisol secretion. Clinical Endocrinology 45, 39-45.
117. Schwartz D, Hernandez L, Hoebel BG (1989). Fenfluramine administered systemically or locally increases extracellular serotonin in the lateral hypothalamus as measured by microdialysis. Brain Research 482, 261-270.
118. Series HG, Cowen PJ, Sharp T (1994). P-chloroamphetamine (PCA), 3,4-methylenedioxy-methamphetamine (MDMA) and d-fenfluramine pretreatment attenuates d-fenfluramine-evoked release of 5-HT in vivo. Psychopharmacology 116, 508-514.
119. Shapira B, Cohen J, Newman ME, Lerer B (1993). Prolactin response to fenfluramine and placebo challenge following maintenance pharmacotherapy withdrawal in remitted depressed patients. Biological Psychiatry 33, 531-535.
120. Shapira B, Lerer B, Kindler S, Lichtenberg P, Gropp C, Cooper T, Calev A (1992a). Enhanced serotonergic responsivity following electroconvulsive therapy in patients with major depression. British Journal of Psychiatry 160, 223-229.
121. Shapira B, Reiss A, Kaiser N, Kindler S, Lerer B, (1989). Effect of imipramine treatment on the prolactin response to fenfluramine and placebo challenge in depressed patients. Journal of Affective Disorders 16, 1-4.
122. Shapira B, Yagmur MJ, Gropp C, Newman ME, Lerer B (1992b). Effect of clomipramine and lithium on fenfluramine-induced hormone release in major depression. Biological Psychiatry 31, 975-983.
123. Sharpe M, Clements A, Hawton K, Young AH, Sargent P, Cowen PJ (1996). Increased prolactin response to buspirone in chronic fatigue syndrome. Journal of Affective Disorders 41, 71-76.
124. Sharpe M, Hawton K, Clements A, Cowen PJ (1997). Increased brain serotonin function in men with chronic fatigue syndrome. British Medical Journal 315, 164-165.
125. Shor-Posner G , Grinker JA, Marinescu C, Brown O, Leibowitz SF (1986). Hypothalamic serotonin in the control of meal patterns and macronutrient selection. Brain Research Bulletin 17, 663-671.
126. Siever LJ, Murphy DL Slater S, de la Vega E, Lipper S (1984). Plasma prolactin changes following fenfluramine in depressed patients compared to controls: an evaluation of central serotonergic responsitivity in depression. Life Sciences 34, 1029-1039.
127. Sommers DK, van Wyk M, Snyman JR (1994). Dexfenfluramine-induced prolactin release as an index of central synaptosomal 5-HT during treatment with fluoxetine. European Journal of Clinical Pharmacology 46, 441-444.
128. Stahl SM, Hauger RL, Rausch JL, Fleishaker JC, Hubbell-Alberts E (1993). Downregulation of serotonin receptor subtypes by nortriptyline and adinazolam in major depressive disorder: neuroendocrine and platelet markers. Clinical Neuropharmacology 16 (Supplement 3), S19-S31.
129. Stoff DM, Pastiempo AP, Yeung JH, Cooper TB, Bridger WH, Rabinovich H (1992). Neuroendocrine responses to challenge with d,l-fenfluramine and aggression in disruptive behaviour disorders of children and adolescents. Psychiatry Research 43, 263-276.
130. Stoff DM, Pastiempo AP, Yeung JH, Bridger WH, Rabinovich H (1992). Test-retest reliability of the prolactin and cortisol responses to d,l-fenfluramine challenge in disruptive behaviour disorders. Psychiatry Research 42, 65-72.
131. Targum SD (1990). Differential responses to anxiogenic challenge studies in patients with major depressive disorder and panic disorder. Biological Psychiatry 28, 21-34.
132. Targum SD, Marshall LE (1989). Fenfluramine provocation of anxiety in patients with panic disorder. Psychiatry Research 28, 295-306.
133. Thakore JH, Dinan TG (1995). Cortisol synthesis inhibition: a new treatment strategy for the clinical and endocrine manifestations of depression. Biological Psychiatry 37, 364-368.
134. Thakore JH, O'Keane V, Dinan TG (1996). D-fenfluramine-induced prolactin responses in mania: evidence for serotonergic subsensitivity. American Journal of Psychiatry 153, 1460-1463.
135. van de Kar LD, Urban JH, Richardson KD, Bethea CL (1985). Pharmacological studies on the serotonergic and non-serotonin-mediated stimulation of prolactin and corticosterone secretion by fenfluramine. Neuroendocrinology 41, 283-288.
136. van de Kar LD, Lorens SA, Urban JH, Bethea CL (1989). Effect of selective serotonin (5-HT) agonists and 5-HT-2 antagonist on prolactin secretion. Neuropharmacology 28, 299-305.
137. van Praag HM, Lemus C, Kahn R (1986). Hormonal probes of central serotonergic activity: do they really exist? Biological Psychiatry 22, 86-98.
138. Volpi R, Caffara P, Boni S, Scaglioni A, Malvezzi L, Saginario A, Chiodera P, Coiro V (1997). ACTH/cortisol involvement in the serotonergic disorder affecting the Parkinsonian brain. Neuropsychobiology 35, 73-78.
139. Weizman A, Mark M, Tyano S, Laron Z (1988). Plasma cortisol, prolactin, growth hormone and immunoreactive β-endorphin response to fenfluramine challenge in depressed patients. Clinical Neuropharmacology 11, 250-256.
140. Yatham LN (1996). Prolactin and cortisol response to fenfluramine challenge in mania. Biological Psychiatry 39, 285-288.
141. Yatham LN, Michalon M (1995). Hormonal responses to dl-fenfluramine challenge are not blunted in seasonal affective disorder. Psychoneuroendocrinology 20, 433-438.
142. Yatham LN, Morehouse RL, Chisholm BT, Haase DA, MacDonald DD, Marrie TJ (1994). Neuroendocrine assessment of serotonin function in chronic fatigue syndrome. Canadian Journal of Psychiatry 40, 93-96.
143. Yatham LN, Steiner M (1993). Neuroendocrine probes of serotonergic function: a critical review. Life Sciences 53, 447-463.
144. Young AH, Rue J, Odontiadis J, Cowen PJ (1998). Lack of effect of hydrocortisone treatment on d-fenfluramine-mediated prolactin release. Psychopharmacology 136, 198-200.